Unpacking ‘Good Quests,’ Christianity, and Caviar Bumps
This week on Uncanny Valley, our hosts ask what impact religion will have on Silicon Valley.
Genetic testing company 23andMe, once a Silicon Valley darling valued at $6 billion, filed for Chapter 11 bankruptcy protection late Sunday as it prepares for a sale of the business. CEO Anne Wojcicki, who cofounded the company in 2006, has also stepped down after months of failed attempts to take the firm private. As uncertainty…
The final category of information DeepSeek reserves the right to collect is data from other sources. If you create a DeepSeek account using Google or Apple sign-on, for instance, it will receive some information from those companies. Advertisers also share information with DeepSeek, its policies say, and this can include “mobile identifiers for advertising, hashed…
The Consumer Financial Protection Bureau proposed a new measure on Friday that could protect your Robux from scammers and hackers. The proposed rule would interpret terms in the Electronic Fund Transfer Act, or EFTA, which has traditionally been used to protect consumers from unauthorized debit transactions, to include some virtual currencies supplied by gaming and…
Meta has a lot at stake in the current FTC lawsuit against it. In theory a negative verdict could result in a company breakup. But CEO Mark Zuckerberg once faced an even bigger existential threat. Back in 2006, his investors and even his employees were pressuring him to sell his two-year-old startup for a quick…
Those allegations of murders-for-hire, in fact, dissuaded the first Trump administration from granting clemency to Ulbricht. The White House in 2020 considered freeing Ulbricht but ultimately rejected the idea because of the alleged role of violence in the case, according to one former government official involved in the process who spoke to WIRED on condition…
After telehealth startups recently lost the ability to sell exact copies of patented GLP-1 weight-loss drugs, some firms have begun turning to a different, less effective medication that has been on the market in the United States since 2010. Often considered a precursor to blockbuster products like Novo Nordisk’s Ozempic and Eli Lilly’s Zepbound, liraglutide…